Using NOACS in Obese Patients: Just One More Thing To Consider With
Anticoagulation?
Abstract
Atrial Fibrillation (AF) poses a significant burden to patients as well
as the healthcare system. It can be a complex diagnosis and requires a
holistic approach to treatment. Every patient with AF should be
evaluated for the need for anticoagulation therapy to prevent systemic
embolization. In those that require long-term anticoagulation, a novel
oral anticoagulation agent (NOAC) has become the drug of choice. In
recent years there have been huge developments in the field of
anticoagulation in AF with the presence of the various NOACs on the
market. However, there remains uncertainty around prescribing in obese
patients.